Lung Cancer Surgery Market Report 2026

The lung cancer surgery market size has grown strongly in recent years. It will grow from $5.33 billion in 2025 to $5.6 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increasing lung cancer incidence rates, expansion of hospital surgical capabilities, availability of trained thoracic surgeons, growing adoption of video-assisted thoracoscopic surgery, rising awareness of early-stage lung cancer treatment.

The lung cancer surgery market size is expected to see steady growth in the next few years. It will grow to $6.73 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing integration of robotic surgery platforms, rising demand for precision surgical outcomes, expansion of specialized cancer care centers, growing investments in surgical technology, increasing adoption of enhanced recovery after surgery protocols. Major trends in the forecast period include increasing adoption of minimally invasive surgical techniques, rising use of robotic-assisted thoracic surgery, growing preference for lung-preserving procedures, expansion of advanced surgical instrument utilization, enhanced focus on post-surgical recovery outcomes.

The rising incidence of lung cancer is expected to drive the growth of the lung cancer surgery market in the coming years. Lung cancer is characterized by the uncontrolled growth of abnormal cells in one or both lungs, which can disrupt normal lung function. The increasing incidence of lung cancer is largely attributed to prolonged exposure to air pollution and fine particulate matter, as these tiny particles can penetrate deep into the lungs, causing inflammation, cellular damage, and mutations that may lead to cancer development. Lung cancer surgery helps reduce lung cancer-related mortality by enabling the early removal of malignant tumors before they can spread or advance. For example, in June 2025, according to the Centers for Disease Control and Prevention, a US-based federal government agency, lung cancer was responsible for 131,584 deaths in the United States in 2023, following 218,893 newly reported cases in 2022. Therefore, the increasing incidence of lung cancer is propelling the growth of the lung cancer surgery market.

Key companies in the lung cancer surgery market are focusing on developing innovative technologies, such as robotic-assisted surgeries, to improve surgical precision, reduce recovery time, and enhance patient outcomes. Robotic-assisted surgeries are minimally invasive procedures performed using robotic systems controlled by surgeons to increase precision, minimize complications, and improve recovery outcomes. For instance, in March 2025, Johnson & Johnson MedTech, a US-based medical devices and technology company, announced regulatory clearance of MONARCH QUEST under U.S. 510(k). The MONARCH QUEST robotic-assisted bronchoscopy platform provides enhanced reach and stability to access small, difficult-to-reach lung nodules, improving early-stage lung cancer diagnosis. Its advanced maneuverability and integration with imaging technologies enable more accurate biopsies while reducing patient discomfort. The platform is designed to expand procedural capabilities, streamline workflow, and support greater clinical confidence and consistency across a wide range of bronchoscopic procedures.

In June 2023, AstraZeneca Pharma India Ltd., an India-based pharmaceutical manufacturing company, partnered with Rajiv Gandhi Cancer Institute and Research Center to enhance lung cancer diagnostic capabilities by establishing a Center of Excellence for early and precise testing. This partnership aims to improve patient outcomes by facilitating timely diagnosis, promoting access to advanced testing technologies, and supporting personalized treatment approaches for lung cancer. Rajiv Gandhi Cancer Institute and Research Center, based in India, offers thoracic surgery services, including minimally invasive techniques such as video-assisted thoracoscopic surgery (VATS) and robotic surgery for lung cancer.

Major companies operating in the lung cancer surgery market are Johnson And Johnson, Medtronic plc, Fujifilm Holdings Corporation, B Braun Melsungen AG, Olympus Corporation, Intuitive Surgical Inc, Teleflex Incorporated, Karl Storz SE, Lepu Medical Technology Beijing Co Ltd, Ambu AS, KLS Martin Group, Richard Wolf GmbH, Ethicon Inc, Ackermann Instrument GmbH, Scanlan International Inc, Sontec Instruments Inc, Covidien LLC, Stryker Corporation, Smith And Nephew plc, CONMED Corporation, Erbe Elektromedizin GmbH.

North America was the largest region in the lung cancer surgery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer surgery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer surgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the lung cancer surgery market by increasing costs of imported robotic surgery systems, thoracoscopes, staplers, and advanced energy instruments used in surgical procedures. Hospitals in North America and Europe are most affected due to reliance on imported high-value surgical equipment, while Asia-Pacific faces cost pressure on device procurement. These tariffs are increasing capital expenditure and procedural costs. However, they are also encouraging local manufacturing partnerships, regional device innovation, and wider adoption of cost-optimized minimally invasive surgical solutions.

The lung cancer surgery market research report is one of a series of new reports that provides lung cancer surgery market statistics, including lung cancer surgery industry global market size, regional shares, competitors with a lung cancer surgery market share, detailed lung cancer surgery market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer surgery industry. This lung cancer surgery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lung cancer surgery is a medical procedure performed to remove cancerous tissue from the lungs. It is typically indicated when the cancer is confined to the lung and has not widely spread. The goal of the surgery is to completely remove the tumor and affected lung tissue to prevent disease progression or recurrence.

The primary types of lung cancer surgery are thoracotomy and minimally invasive surgeries. A thoracotomy involves making an incision in the chest wall to access the lungs or other organs in the chest. Procedures include lobectomy, segmentectomy, pneumonectomy, sleeve resection, and extended resection, performed using products such as thoracoscopes, mediastinoscopes, bronchoscopes, robotic-assisted thoracic surgery systems, surgical staplers, surgical energy instruments, advanced energy instruments, advanced bipolar instruments, ultrasonic instruments, and others. These products are distributed through multiple channels, including direct tender, retail sales, online sales, and others, and are used by end users including hospitals, ambulatory and surgical centers, academic and research institutes, specialty cancer care centers, and others.

The lung cancer surgery market consists of revenues earned by entities providing services such as preoperative and postoperative care, follow-up and monitoring and surgical procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer surgery market includes sales of products such as surgical instruments, stapling devices, electrosurgical units, thoracoscopes, and robotic surgical systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.